This episode is in partnership with Boston Biotechnology Summit, a bridge to collaboration and innovative synergies between healthcare stakeholders. In this episode, I hosted Jonathan Levy CEO of Pepkon, the biotech focused on developing first-in-class therapeutic peptides for oncology, who won the first prize in BBS 2024. Jonathan, who has a background in pharmacy and management, shared his journey from various roles in the French healthcare sector to leading Pepcon. He emphasized the importance of humility, listening, and learning in leadership, as well as recruiting a skilled team that shares the company's values. Under his leadership, Pepcon has raised significant funding and aims to start its first human clinical trials next year. Viewing his work as a mission to improve patient outcomes, Jonathan stressed the importance of scientific innovation and collaboration in advancing healthcare. "It's more than a job, it's a mission" MEET OUR GUEST Jonathan Levy, Chief Executive Officer of Pepkon. Jonathan Levy is CEO of Pepkon. He is a Pharmacist from University of Paris with a masters in management from ESSEC Business school. He has worked in various environment of the healthcare sector in France from pharmacy to hospital, and also in big pharma and startups. His last role before joining Pepkon was within Truffle Capital a French VC; where he participated in several investments in biotech and also company creations, M&A and licensing deals. Two years ago Jonathan joined PepKon, a startup developing first-in-class therapeutic peptides in oncology, first as a COO, and now leading the company as its CEO.